Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2copper dotatate CU-64 2Etoposide 2zimberelimab 1folfirinox 1famitinib 1cabozantinib 1abemaciclib 1Temozolomide 1Nivolumab 1Lutetium-177 1Lutetium 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Cytokines 1Cryotherapy 1Copper 1Cisplatin 1Carboplatin 1Acupuncture Therapy 1Acupressure 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastro-enteropancreatic neuroendocrine tumor × Cytokines × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡